ClinicalTrials.gg
Not yet recruitingNCT07155694Updated Aug 21, 2026

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

A Phase 4 interventional study of Finerenone 10 MG and Empagliflozin 10 MG in Diabetic Kidney Disease, sponsored by Washington D.C. Veterans Affairs Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 20 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Washington D.C. Veterans Affairs Medical Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Planned enrollment
9th of 10
30 · median 108
Started
2026
with 4 others
Phase 4
3 of 10
3 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Washington D.C. Veterans Affairs Medical Center

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one is the 9th largest by planned enrollment, is one of 5 that started in 2026, is one of 3 in phase 4, and was the 6th registered.

Diabetic Nephropathies

544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 20 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy.

Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).

Read the detailed description

Chronic kidney disease (CKD) is a complex medical condition imposing deleterious effects on multiple organ systems. Prevention of increased cardiovascular mortality and progression to end-stage kidney disease (ESKD) are two major unmet medical needs in patients with CKD, with or without diabetes mellitus, especially in those with albuminuria. In patients with Diabetic Kidney Disease (DKD), the cornerstone of management includes blood pressure control, proteinuria management, maintenance of normal body weight, dietary adherence, and avoidance of nephrotoxic drugs. The management of DKD has undergone extensive changes with the advent of several foundational classes of guideline-based medical therapies (GDMT) for DKD. These include SGLT2i, GLP1-RAs along with Renin-Angiotensin System-inhibitors (RASi). While the benefits of the SGLT2i class of diabetes medications such as Empagliflozin for cardio-kidney outcomes in CKD are well recognized from the landmark EMPA-REG trial, there is less understood in terms of mechanisms of benefit, especially in high-risk patient phenotypes for progression to kidney failure, such as APOL1 positive gene mutation. The results from the recent FIDELIO-DKD and FIGARO-DKD studies showed that finerenone (an aldosterone receptor inhibitor) resulted in a decreased risk of cardiovascular events and slows down CKD progression in patients with type 2 diabetes (T2DM). This was a significant breakthrough and adds an additional class of medication for the treatment of DKD. However, the generalizability of the findings was limited as only 4.7% of the patients were African-American.

The Veterans Health Administration is the largest integrated healthcare system in the USA providing a comprehensive database of patients with CKD. The Nephrology and Endocrinology divisions at DC VAMC manage 175 new CKD patients each month (of whom 70% have diabetes) and 95% are African Americans. African Americans suffer from CKD at significantly higher rates and account for more than 35% of all patients receiving dialysis in the United States. Aggressive management with newer T2DM meds with reno-protective effects is important to be started early. Recently identified genetic variants in the APOL1 gene, found mostly in African Americans may explain a significant proportion of the rising burden of albuminuric CKD in African Americans. APOL1 risk variants G1 and G2 are trypanolytic factors that protect against trypanosomiasis in continental Africa but are associated with a significantly higher risk for the development of podocytopathy and ultimately progressive CKD. Though CKD is quite prevalent in African American patients, the precise mechanism of APOL1 risk variants leading to the progression of DKD in this patient population is unknown and requires further investigation. Interestingly the studies on APOL1 nephropathy have established an association with podocytopathy. Abnormalities in podocyte biology play a central role in the pathogenesis of albuminuric CKD. In CKD with albuminuria, podocyte injury is a key component in the pathophysiology of albuminuric CKD, which is also accompanied by systemic inflammation. The degree of podocyte injury is currently best assessed by kidney biopsy, which is an invasive procedure and not performed in the vast majority of patients with CKD. Therefore, the patterns and extent of podocyte injury in albuminuric CKD is less well understood. The investigators and others have shown improved endothelial function and decreased podocyte-specific urine protein injury markers production with SGLT2i in DKD. Additionally, the literature suggests close crosstalk between the glomerular vascular endothelium and the podocyte. The effect of Finerenone and SGLT2i on markers of podocyte injury, as well as markers of endothelial dysfunction (injury/inflammation) deserve further elucidation, either each medication on its own or in combination in African Americans with proteinuria.

The comparator in this study is Empagliflozin which is a standard of care in DKD. However, the investigators hypothesize that the combination will be more efficacious that either medication alone and synergistic for podocytopathy and proteinuria reversal similar to CONFIDENCE trial even in a CKD prone population of African Americans with diabetes

03

Conditions studied

  • Diabetic Kidney Disease

Keywords

  • Empagliflozin
  • Finerenone
  • Empagliflozin and Finerenone combination
  • Podocyte Injury
  • Chronic Kidney Disease
  • Diabetic Kidney Disease
  • Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of type 2 diabetes ( at or above 6.5%, or fasting blood glucose of more than 125 or random/ post prandial blood glucose of more than 199mg%)
  2. African American veterans
  3. Age 20-90 years
  4. ≥25-89 mL/min/1.73 m2 by the CKD-EPI equation)
  5. Albuminuria of 30 mg/g or higher
  6. =18-39.9
  7. Blood pressure controlled to ≤140/90
  8. Ability to provide before any trial related activities are conducted.

Exclusion criteria

Exclusion Criteria

  1. If a patient is on statin, need to be on a stable dose for a month.
  2. proven diagnosis of glomerular disease/glomerulonephritis
  3. Active smokers,
  4. Active skin wounds undergoing treatment or recent surgery within 1 month (due to possible aberrations in glycemic control)
  5. Women who are pregnant, planning to become pregnant, nursing mothers, women of not using measure
  6. to empagliflozin or finerenone
  7. Patients on dialysis
  8. less than 25 mL/min/1.73 m2 by the CKD-EPI equation
  9. Planned surgery or planned hospital admission within 5 months of participation in the study
  10. At the discretion of PI to ensure health, safety, and well-being of the veteran, participation in this study may be stopped (please see withdrawal criteria)
  11. Patients with prior history of diagnosis of heart failure with documented EF of less than 50.
  12. Proven diagnosis of Polycystic Kidney Disease.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Finerenone

    Finerenone 10mg orally daily for 4 months

    Drug: Finerenone 10 MG

  • Active comparator
    Empagliflozin

    Empagliflozin 10mg orally daily for 4 months

    Drug: Empagliflozin 10 MG

  • Active comparator
    Finerenone and Empagliflozin combination

    Take 10mg Empagliflozin daily, followed by Fineronone 10mg daily after 4 weeks or 1 month of taking empagliflozin. The combination will continue for 3 months or 12 weeks

    Drug: Finerenone 10 MG · Drug: Empagliflozin 10 MG

Interventions

06

What researchers measure

Primary outcomes

  1. Urine Exosome Assay

    To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine on empagliflozin or finerenone or combination therapy. Protein western analysis of Exosomes released from Kidney Podocyte is a indicator of kidney Podocyte health. Expressed as a ratio normalized

    Time frame: 16 weeks

Secondary outcomes

  1. Renal Function - urine

    Assessing kidney function by Microalbumin/Creatinine Ratio (Proteinuria) in the urine

    Time frame: 16 weeks

  2. Renal Function - serum

    Estimated glomerular Filtration Rate (Egfr) assessing kidney function based on factors such as creatinine in the serum, age, sex, and ethnicity.

    Time frame: 16 weeks

  3. CD34 positive Cell Migratory Function

    Proportion of cells that migrate through SDF1a in a transwell assay. A larger value indicates better migratory function of the CD34+ cells.

    Time frame: 16 weeks

  4. CD34 positive Cell Gene Expression

    Evaluate mRNA gene expression focusing on vascular and endothelial function systemic markers which is normalized to 18s. Fold change of Gene Expression in participants with DKD relative to visit 1.

    Time frame: 16 weeks from visit 1

  5. CD34+ Endothelial Cell Colony Formation Unit (CFU)

    CFU count of CD34+ endothelial progenitor cells (EPCs)

    Time frame: 16 weeks

  6. Arterial Stiffness - Pulse Wave Velocity (PWV)

    Vessel health assessed by using arterial tonometry with the SphygmoCor CP system from ATCOR.

    Time frame: 16 weeks

  7. Arterial Stiffness - Pulse Wave Analysis Augmentation Index

    Augmentation index was calculated via tonometry with Sphygmocor Device from AtCor (Pulse Wave Analysis). Augmentation index is calculated as the augmentation pressure (the amplitude of the reflected pulse wave) divided by the pulse pressure (systolic - diastolic) \* 100 to give a percentage of pulse pressure. The software then calculates an estimated Augmentation Index at heart rate of 75 as a form of "normalization." The higher the values the higher the cardiovascular risk.

    Time frame: 16 weeks

  8. Arterial Stiffness - Pulse Wave Analysis Augmentation Pressure

    Augmentation Pressure is the amplitude of the reflected pulse wave calculated via tonometry with Sphygmocor Device (Pulse Wave Analysis). The higher the values the higher the cardiovascular risk.

    Time frame: 16 weeks

  9. Arterial Stiffness - Pulse Wave Analysis Augmentation Index 75

    Vessel health is assessed by looking at Arterial stiffness via tonometry. Augmentation index (AI) is defined as the ratio of the augmentation pressure to the pulse pressure, times 100, to give a percentage. Augmentation index 75 normalizes this value to an estimate of the AI at a heart rate of 75bpm. We used Vascular Flow and wave measurement equipment, SphygmoCor Central Pressure system from AtCor. The higher the values the higher the cardiovascular risk.

    Time frame: 16 weeks

  10. Hip to Waist Ratio

    Ratio of Hip to Waist

    Time frame: 16 weeks

  11. Body Composition: BMI

    Body mass index measured using Biometric Impedance Scale in kilogram per square metre

    Time frame: 16 weeks

  12. Body Composition: Body Fat Percent

    Percent of Body Fat measured using Biometric Impedance Tanita Scale

    Time frame: 16 weeks

  13. Body Composition: Body Water percent

    Percent of Body Water measured using Biometric Impedance Tanita Scale

    Time frame: 16 weeks

  14. Biochemistry: Hemoglobin A1C (HbA1c)

    HbA1c percent

    Time frame: 16 weeks

  15. Fasting Lipid Profile

    Measured from a serum blood Lipid Panel: Total Cholesterol, LDL, HDL, and Triglycerides

    Time frame: 16 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2027, 9 months later.

Of 21 phase 4 interventional studies under Diabetic Nephropathies, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Sep 4, 2025
StartEst.
Oct 1, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Aug 2027
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07155694
Lead sponsor
Washington D.C. Veterans Affairs Medical Center
Collaborators
Bayer
Responsible party
Sabyasachi Sen, MD, PhD (Chief of Endocrinology, Washington D.C. Veterans Affairs Medical Center) — Principal investigator
First posted
Sep 4, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Aug 21, 2026

Study contacts

Sabyasachi Sen, MD, PhD
Contact
sabyasachi.sen@va.gov
202-745-8000 ext. 55810
Shannen Nicole D Ubalde, MS
Contact
shannen.ubalde@va.gov
202-745-8000 ext. 55835
Sabyasachi Sen, MD, PhD
principal investigator · Washington DC VA Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finerenone · Empagliflozin

Start the discussion